Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Active | |||
TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
TBC | momelotinib | Myelofibrosis | Pending | |||
TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Suspended | |||
TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
TBD | Cabozantinib | Withdrawn | ||||
TBD | Entrectinib | Withdrawn | ||||
TBD | Bevacizumab | Cancelled |